These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35055342)
1. Reduced Incidence of Stroke in Patients with Gout Using Benzbromarone. Niu SW; Hung CC; Lin HY; Kuo IC; Huang JC; He JS; Wen ZH; Liang PI; Chiu YW; Chang JM; Hwang SJ J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055342 [TBL] [Abstract][Full Text] [Related]
2. Decreased incidence of diabetes in patients with gout using benzbromarone. Niu SW; Chang KT; Ta A; Chang YH; Kuo IC; Hung CC; Chiu YW; Hwang SJ; Lin SF; Lin HY Rheumatology (Oxford); 2018 Sep; 57(9):1574-1582. PubMed ID: 29796661 [TBL] [Abstract][Full Text] [Related]
3. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Kang EH; Park EH; Shin A; Song JS; Kim SC Eur Heart J; 2021 Nov; 42(44):4578-4588. PubMed ID: 34508567 [TBL] [Abstract][Full Text] [Related]
5. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260 [TBL] [Abstract][Full Text] [Related]
6. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. Kang EH; Shin A; Park CS; Lee EB; Lee YJ; Curhan G; Choi HK Rheumatology (Oxford); 2024 Sep; 63(9):2433-2441. PubMed ID: 38733596 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout. Eun Y; Han H; Kim K; Kang S; Lee S; Kim H; Lee J; Koh EM; Cha HS Ther Adv Musculoskelet Dis; 2022; 14():1759720X221116409. PubMed ID: 35966182 [TBL] [Abstract][Full Text] [Related]
8. Decreased incidence of gout in diabetic patients using pioglitazone. Niu SW; Chang KT; Lin HY; Kuo IC; Chang YH; Chen YH; Hung CC; Chiu YW; Hwang SJ Rheumatology (Oxford); 2018 Jan; 57(1):92-99. PubMed ID: 29040733 [TBL] [Abstract][Full Text] [Related]
9. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. Chang HW; Lin YW; Lin MH; Lan YC; Wang RY PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649 [TBL] [Abstract][Full Text] [Related]
10. The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan. Lai SW; Liao KF; Kuo YH; Hwang BF; Liu CS Medicine (Baltimore); 2023 Feb; 102(5):e32779. PubMed ID: 36749254 [TBL] [Abstract][Full Text] [Related]
11. Association Between Use of Anti-gout Preparations and Dementia: Nested Case-Control Nationwide Population-Based Cohort Study. Chuang TJ; Wang YH; Wei JC; Yeh CJ Front Med (Lausanne); 2020; 7():607808. PubMed ID: 33511144 [No Abstract] [Full Text] [Related]
12. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. Xue X; Liu Z; Li X; Lu J; Wang C; Wang X; Ren W; Sun R; Jia Z; Ji X; Chen Y; He Y; Ji A; Sun W; Zhang H; Merriman TR; Li C; Cui L Rheumatology (Oxford); 2021 Jun; 60(6):2661-2671. PubMed ID: 33211886 [TBL] [Abstract][Full Text] [Related]
13. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161 [TBL] [Abstract][Full Text] [Related]
14. A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia. Lai SW; Liao KF; Kuo YH; Lin CL; Liu CS; Hwang BF Front Pharmacol; 2021; 12():731370. PubMed ID: 34658871 [No Abstract] [Full Text] [Related]
15. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978 [TBL] [Abstract][Full Text] [Related]
16. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Lee MH; Graham GG; Williams KM; Day RO Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784 [TBL] [Abstract][Full Text] [Related]
17. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194 [TBL] [Abstract][Full Text] [Related]
18. Cancer risk in Korean patients with gout. Oh YJ; Lee YJ; Lee E; Park B; Kwon JW; Heo J; Moon KW Korean J Intern Med; 2022 Mar; 37(2):460-467. PubMed ID: 32872748 [TBL] [Abstract][Full Text] [Related]
19. Serum CRP in patients with gout and effects of benzbromarone. Okuda C; Koyama H; Tsutsumi Z; Yamamoto A; Kurajoh M; Moriwaki Y; Yamamoto T Int J Clin Pharmacol Ther; 2011 Mar; 49(3):191-7. PubMed ID: 21329621 [TBL] [Abstract][Full Text] [Related]
20. Clinical Association between Gout and Parkinson's Disease: A Nationwide Population-Based Cohort Study in Korea. Kim JH; Choi IA; Kim A; Kang G Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946237 [No Abstract] [Full Text] [Related] [Next] [New Search]